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PREAMBLE
Keeping pace with the stream of new data and evolving
evidence on which guideline recommendations are based is
an ongoing challenge to timely development of clinical
practice guidelines. In an effort to respond promptly to new
evidence, the American College of Cardiology Founda-
tion/American Heart Association (ACCF/AHA) Task
Force on Practice Guidelines (Task Force) has created a
“focused update” process to revise the existing guideline
recommendations that are affected by the evolving data or
opinion. New evidence is reviewed in an ongoing fashion to
more efficiently respond to important science and treat-
ment trends that could have a major impact on patient
outcomes and quality of care. Evidence is reviewed at least
twice a year, and updates are initiated on an as-needed basis
and completed as quickly as possible while maintaining the tigorous methodology that the ACCF and AHA have de-
eloped during their partnership of 20 years.
These updated guideline recommendations reflect a
onsensus of expert opinion after a thorough review pri-
arily of late-breaking clinical trials identified through a
road-based vetting process as being important to the
elevant patient population, as well as other new data
eemed to have an impact on patient care (see Section 1.1,
ethodology and Evidence Review, for details). This fo-
used update is not intended to represent an update based
n a complete literature review from the date of the previ-
us guideline publication. Specific criteria/considerations
or inclusion of new data include the following:
● publication in a peer-reviewed journal;
● large, randomized, placebo-controlled trial(s);
● nonrandomized data deemed important on the basis
of results affecting current safety and efficacy as-
sumptions, including observational studies and
meta-analyses;
● strength/weakness of research methodology and
findings;
● likelihood of additional studies influencing current
findings;
● impact on current and/or likelihood of need to de-
velop new performance measure(s);
● request(s) and requirement(s) for review and update
from the practice community, key stakeholders, and
other sources free of relationships with industry or
other potential bias;
● number of previous trials showing consistent results;
and
● need for consistency with a new guideline or guideline
updates or revisions.
Selected members of the previous writing committee as
ell as other experts in the subject under consideration are
hosen by the ACCF and AHA to examine subject-specific
ata and towrite guidelines in partnershipwith representatives
rom other medical organizations and specialty groups. Writ-
ng group members review the selected late-breaking clinical
rials and other new data that have been vetted through the
ask Force; weigh the strength of evidence for or against
articular tests, treatments, or procedures; and include esti-
ates of expected outcomes where such data exist. Patient-
pecific modifiers, comorbidities, and issues of patient prefer-
nce that may influence the choice of tests or therapies are
onsidered. When available, information from studies on cost
s considered, but data on efficacy and outcomes constitute
he primary basis for the recommendations contained herein.
In analyzing the data and developing recommenda-
ions and supporting text, the writing group uses evidence-
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Class of Recommendation (COR) is an estimate of the size
of the treatment effect considering risks versus benefits in
addition to evidence and/or agreement that a given treat-
ment or procedure is or is not useful/effective or in some
situations may cause harm. The Level of Evidence (LOE) is
an estimate of the certainty or precision of the treatment
effect. The writing group reviews and ranks evidence sup-
porting each recommendation with the weight of evidence
Table I. Applying classification of recommendations and L
A recommendation with Level of Evidence B or C does not imply that th
guidelines do not lend themselves to clinical trials. Although randomized tria
or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efficacy
myocardial infarction, history of heart failure, and prior aspirin use.
†For comparative effectiveness recommendations (Class I and IIa; Level of
involve direct comparisons of the treatments or strategies being evaluated.ranked as LOE A, B, or C according to specific definitions chat are included in Table I. Studies are identified as obser-
ational, retrospective, prospective, or randomized where
ppropriate. For certain conditions for which inadequate
ata are available, recommendations are based on expert
onsensus and clinical experience and are ranked as LOEC.
hen recommendations at LOE C are supported by his-
orical clinical data, appropriate references (including clin-
cal reviews) are cited if available. For issues for which sparse
ata are available, a survey of current practice among the
of evidence
mmendation is weak. Many important clinical questions addressed in the
unavailable, there may be a very clear clinical consensus that a particular test
ferent subpopulations, such as sex, age, history of diabetes, history of prior
ce A and B only), studies that support the use of comparator verbs shouldevel
e reco
ls are
in dif
Evidenlinicians on the writing group is the basis for LOE C
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for COR and LOE is summarized in Table I, which also
provides suggested phrases for writing recommendations
within each COR. A new addition to this methodology is a
separation of the Class III recommendations to delineate
whether the recommendation is determined to be of “no
benefit” or is associated with “harm” to the patient. In
addition, in view of the increasing number of comparative
effectiveness studies, comparator verbs and suggested
phrases for writing recommendations for the comparative
effectiveness of one treatment or strategy versus another
have been added for COR I and IIa, LOE A or B only.
In view of the advances in medical therapy across the
spectrum of cardiovascular diseases, the Task Force has
designated the term guideline-directed medical therapy
(GDMT) to represent optimal medical therapy as defined
by ACCF/AHA guideline-recommended therapies (pri-
marily Class I). This new term, GDMT, will be used herein
and throughout all future guidelines.
Because the ACCF/AHA practice guidelines address
patient populations (and healthcare providers) residing in
North America, drugs that are not currently available in
North America are discussed in the text without a specific
COR. For studies performed in large numbers of subjects
outside North America, each writing group reviews the
potential influence of different practice patterns and patient
populations on the treatment effect and relevance to the
ACCF/AHA target population to determine whether the
findings should inform a specific recommendation.
The ACCF/AHA practice guidelines are intended to
assist healthcare providers in clinical decision making by de-
scribing a range of generally acceptable approaches to the
diagnosis, management, and prevention of specific diseases or
conditions. The guidelines attempt to define practices that
meet the needs of most patients in most circumstances. The
ultimate judgment regarding care of a particular patient must
be made by the healthcare provider and patient in light of all
the circumstances presented by that patient. As a result, situ-
ations may arise for which deviations from these guidelines
may be appropriate. Clinical decision making should involve
consideration of the quality and availability of expertise in the
area where care is provided.When these guidelines are used as
the basis for regulatory or payer decisions, the goal should be
improvement in quality of care. The Task Force recognizes
that situations arise in which additional data are needed to
inform patient care more effectively; these areas will be iden-
tified within each respective guideline when appropriate.
Prescribed courses of treatment in accordance with these
recommendations are effective only if followed. Because lack
of patient understanding and adherence may adversely affect
outcomes, physicians and other healthcare providers should
make every effort to engage the patient’s active participation in
prescribed medical regimens and lifestyles. In addition, pa-
tients should be informed of the risks, benefits, and alterna-
tives to a particular treatment and be involved in shared
decision making whenever feasible, particularly for COR IIa
and IIb, for which the benefit-to-risk ratio may be lower. oThe Task Force makes every effort to avoid actual,
otential, or perceived conflicts of interest that may arise as
result of industry relationships or personal interests
mong the members of the writing group. All writing
roup members and peer reviewers of the guideline are
sked to disclose all such current relationships as well as
hose existing 12 months previously. In December 2009,
he ACCF and AHA implemented a new policy for relation-
hips with industry and other entities (RWI) that requires
he writing group chair plus a minimum of 50% of the
riting group to have no relevant RWI (Appendix I for the
CCF/AHA definition of relevance). These statements are
eviewed by the Task Force and all members during each
onference call and/or meeting of the writing group and
re updated as changes occur. All guideline recommenda-
ions require a confidential vote by the writing group and
ust be approved by a consensus of the voting members.
embers are not permitted to write, and must recuse
hemselves from voting on, any recommendation or section
o which their RWI apply. Members who recused them-
elves from voting are indicated in the list of writing group
embers, and section recusals are noted in Appendix I.
uthors’ and peer reviewers’ RWI pertinent to this guide-
ine are disclosed in Appendixes I and II, respectively.
dditionally, to ensure complete transparency, writing
roup members’ comprehensive disclosure information—
ncluding RWI not pertinent to this document—is available
s an online supplement. Comprehensive disclosure infor-
ation for the Task Force is also available online at www.
ardiosource.org/ACC/About-ACC/Leadership/Guidelines-
nd-Documents-Task-Forces.aspx. The work of the
riting group was supported exclusively by the ACCF and
HA without commercial support. Writing group mem-
ers volunteered their time for this activity.
In an effort tomaintain relevance at the point of care for
racticing physicians, the Task Force continues to oversee
n ongoing process improvement initiative. As a result, in
esponse to pilot projects, several changes to these guide-
ines will be apparent, including limited narrative text and a
ocus on summary and evidence tables.
The recommendations in this focused update will be
onsidered current until they are superseded by another
ocused update or the full-text guideline is revised. Guide-
ines are official policy of both the ACCF and AHA.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
. INTRODUCTION
.1. Methodology and evidence review
The results of late-breaking clinical trials presented at
he annual scientific meetings of the ACC, AHA, European
ociety of Cardiology, Society for Vascular Surgery, Society
f Interventional Radiology, and Society for Vascular Med-
cine, as well as selected other data/articles published
hrough December 2010, were reviewed by the 2005
uideline writing committee along with the Task Force and
ther experts to identify those trials and other key data that
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the criteria/considerations noted above, recent trial data
and other clinical information were considered important
enough to prompt a focusedupdate of the “ACC/AHA2005
Guidelines for the Management of Patients With Peripheral
Arterial Disease (Lower Extremity, Renal, Mesenteric, and
Abdominal Aortic).”2 Because clinical research and clinical
care of vascular disease have a global investigative and interna-
tional clinical care tradition, efforts were made to harmonize
this update with the Trans-Atlantic Inter-Society Consensus
document on Management of Peripheral Arterial Disease
(TASC) and the Inter-Society Consensus for the Manage-
ment of Peripheral Arterial Disease (TASC II) Steering
Committee guideline writing efforts.3
To provide clinicians with a comprehensive set of data,
whenever deemed appropriate or when published, the abso-
lute risk difference and number needed to treat or harm are
provided in the guideline, along with confidence intervals
(CIs) and data related to the relative treatment effects, such as
odds ratio, relative risk,hazard ratio (HR),or incidence rate ratio.
Consult the full-text version2 or executive summary4 of
the “ACC/AHA 2005 Guidelines for the Management of
Patients With Peripheral Arterial Disease (Lower Extremity,
Renal,Mesenteric, andAbdominal Aortic)” for policy on clinical
areas not covered by the focused update. Individual recommen-
dationsmodified in this focused updatewill be incorporated into
future revisions and/or updates of the full-text guideline.
1.2. Organization of the writing group
For this focused update, all eligible members of the
2005 writing committee were invited to participate; those
who agreed (referred to as the 2011 focused update writing
group) were required to disclose all RWI relevant to the
data under consideration. In addition, new members were
invited in order to preserve the required RWI balance. The
writing group included representatives from the ACCF,
AHA, Society for Cardiovascular Angiography and Inter-
ventions, Society of Interventional Radiology, Society for
Vascular Medicine, and Society for Vascular Surgery.
1.3. Document review and approval
This document was reviewed by 2 official reviewers
each nominated by the ACCF and the AHA, as well as 2
reviewers each from the Society for Cardiovascular Angiog-
raphy and Interventions, Society of Interventional Radiol-
ogy, Society for Vascular Medicine, and Society for Vascu-
lar Surgery; and 13 individual content reviewers (including
members from the following groups: ACCF/AHA Task
Force on Clinical Data Standards, ACCF Interventional
Scientific Council, 2005 Peripheral Artery Disease Writing
Committee, ACCF/AHA Task Force on Performance
Measures, ACCF Prevention Committee, and ACCF Pe-
ripheral Vascular Disease Committee). All information on
reviewers’ RWI was distributed to the writing group and is
published in this document (Appendix II).
This document was approved for publication by the
governing bodies of the ACCF and AHA and endorsed by
the Society for Cardiovascular Angiography and Interven- Iions, Society of Interventional Radiology, Society for Vas-
ular Medicine, and Society for Vascular Surgery.
.4. Scope of the focused update
Studies relevant to the management of patients with
eripheral artery disease (PAD) (lower extremity, renal,
esenteric, and abdominal aortic) were identified and re-
iewed as described previously in Section 1.1. On the basis
f these data, the writing group determined that updates to
he 2005 recommendations were necessary for lower ex-
remity and abdominal aortic disease but that the existing
ecommendations for renal and mesenteric disease remain
alid.4 Although the specific recommendations for renal
nd mesenteric disease did not change, the following ob-
ervations and clarifications were made:
. Medical therapy for renal disease: No new pivotal trials
or studies were identified.
. Revascularization for renal disease: The writing group
acknowledges that some new studies support a more lim-
ited role for renal revascularization. For example, the AS-
TRAL (Angioplasty and Stent for Renal Artery Lesions)
investigators5 concluded that there were substantial risks
but no clinical benefit from revascularization in patients
with atherosclerotic renovascular disease. The writing
group concurred that the criteria for patient selection in
this randomized controlled trial (RCT) potentially ex-
cluded many patients who might have benefitted from
intervention. It is anticipated that ongoing studies such as
the CORAL (Cardiovascular Outcomes in Renal Athero-
sclerotic Lesions) trial6 will provide additional evidence
relevant to these recommendations in the near future.
. Methods of revascularization for renal disease: The
2005 recommendations remain current.
The 2011 focused update acknowledges the declining
se of surgical revascularization and the increasing use of
atheter-based revascularization for renal artery stenoses.
he writing group determined that new data support the
quivalency of surgical and endovascular treatment, with
owermorbidity andmortality associated with endovascular
reatment but higher patency rates with surgical treatment
n those patients who survived for at least 2 years after
andomization.5 The writing group also notes that new
ata suggest that 1) the efficacy of revascularization may be
educed in patients with branch artery stenoses7 and 2)
atients undergoing renal artery bypass may do best when
urgery is performed in high-volume centers.8
. LOWER EXTREMITY PAD
.5. Diagnostic methods
2.5.1. Recommendations for ankle-brachial index,
oe-brachial index, and segmental pressure examina-
ion. Table II contains recommendations for ankle-brachial
ndex (ABI), toe-brachial index, and segmental pressure ex-
mination. See Appendix III for supplemental information.
The German Epidemiologic Trial on Ankle Brachial
ndex Study Group included 6880 patients 65 years of
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asymptomatic or symptomatic PAD.11 On the basis of this
large epidemiologic study, the 2011 writing group modi-
fied the age for consideration of ABI diagnostic testing to
65 years. The writing group considered the potential
impact of lowering the PAD detection age to 65 years,
acknowledging that the ABI test would be used in an
incrementally larger “at-risk” population. This reflects the
intent of both the original evidence-based document and
this focused update to blunt the profound ongoing under-
diagnosis and undertreatment of individuals with PAD
until limb ischemic symptoms have become severe. This
ABI recommendation is intended for office-based and vas-
cular laboratory diagnostic use and is not intended to serve
as a population screening tool. The writing group noted
with confidence that no other cardiovascular disease diag-
nostic test can be applied in an age-defined clinical popula-
tion with such a high detection rate, low to no risk, and low
cost. We encourage expansion of the evidence base by
design and completion of ABI screening studies.
The definitions of normal and abnormal ABI values
have been modified based on publication of the results of
the Ankle Brachial Index Collaboration.24 This includes a
normal ABI range of 1.00 to 1.40, and abnormal values
continue to be defined as those 0.90. ABI values of 0.91
to 0.99 are considered “borderline” and values 1.40
indicate noncompressible arteries.
The 2005 recommendations stated that segmental pres-
sure measurements are useful in the diagnosis and anatomic
localization of lower extremity PAD. The 2011writing group
recognized that vascular diagnostic laboratories could use
segmental pressures, Doppler waveform analysis, pulse vol-
Table II. Recommendations for ankle-brachial index, toe-
2005 Recommendations 2
Class I
The resting ABI should be used to establish the lower
extremity PAD diagnosis in patients with suspected lower
extremity PAD, defined as individuals with exertional leg
symptoms, with nonhealing wounds, who are 70 years and
older or who are 50 years and older with a history of
smoking or diabetes. (Level of Evidence: C)
1. Th
the
wit
as i
exe
age
wit
(Le
The ABI should be measured in both legs in all new patients
with PAD of any severity to confirm the diagnosis of lower
extremity PAD and establish a baseline.12–14
(Level of Evidence: B)
The toe-brachial index should be used to establish the lower
extremity PAD diagnosis in patients in whom lower
extremity PAD is clinically suspected but in whom the ABI
test is not reliable due to noncompressible vessels (usually
patients with long-standing diabetes or advanced age).15–19
(Level of Evidence: B)
Leg segmental pressure measurements are useful to establish
the lower extremity PAD diagnosis when anatomic
localization of lower extremity PAD is required to create a
therapeutic plan.20–23 (Level of Evidence: B)
2. AB
non
1.4
0.9
(Le
ABI, Ankle-brachial index; and PAD, peripheral artery disease.ume recordings, or ABI with duplex ultrasonography (or Aome combination of these methods) to document the pres-
nce and location of PAD in the lower extremity.
.6. Treatment
2.6.1.4. Recommendations for smoking cessa-
ion. Table III contains recommendations for smoking
essation. See Appendix III for supplemental information.
No prospective RCTs have examined the effects of smok-
ng cessation on cardiovascular events in patients with lower
xtremity PAD.Observational studies have found that the risk
f death, myocardial infarction, and amputation is substan-
ially greater, and lower extremity angioplasty and open sur-
ical revascularization patency rates are lower in individuals
ith PAD who continue to smoke than in those who stop
moking.34–36 In some studies, exercise time is greater in
atients who stop smoking than in current smokers.37,38
fforts to achieve smoking cessation are recommended for
atients with lower extremity PAD. Physician advice coupled
ith frequent follow-up achieves 1-year smoking cessation
ates of approximately 5% compared with only 0.1% in indi-
iduals who try to quit smoking without a physician’s inter-
ention.39 With pharmacological interventions such as nico-
ine replacement therapy and bupropion, 1-year smoking
essation rates of approximately 16% and30%, respectively, are
chieved in a general population of smokers.33
Varenicline, a nicotinic receptor partial agonist, has
emonstrated superior quit rates when compared with
icotine replacement and bupropion in several RCTs.30–32
he superior smoking cessation may result from better
eductions in craving and withdrawal symptoms.40 Despite
ts greater cost, varenicline is cost-effective because of its
mproved quit rates.41 In 2009, the US Food and Drug
hial index, and segmental pressure examination
ocused Update Recommendations Comments
g ABI should be used to establish
extremity PAD diagnosis in patients
ected lower extremity PAD, defined
uals with 1 or more of the following:
l leg symptoms, nonhealing wounds,
ars and older, or 50 years and older
tory of smoking or diabetes.9–11
vidence: B)
Modified recommendation (age
modified and level of
evidence changed from
C to B).
2005 recommendation remains
current in 2011 focused
update.
2005 recommendation remains
current in 2011 focused
update.
2005 recommendation remains
current in 2011 focused
update.
ts should be uniformly reported with
ressible values defined as greater than
mal values 1.00 to 1.40, borderline
.99, and abnormal 0.90 or less.24
vidence: B)
New recommendationbrac
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with reports of changes in behavior such as hostility, agita-
tion, depressed mood, and suicidal thoughts or actions. In
patients with PAD specifically, comprehensive smoking
cessation programs that included individualized counseling
and pharmacological support significantly increased the
rate of smoking cessation at 6 months compared with
verbal advice to quit smoking (21.3% versus 6.8%,
P0.02).29 Tobacco cessation interventions are particu-
larly critical in individuals with thromboangiitis obliterans,
because it is presumed that components of tobacco may be
causative in the pathogenesis of this syndrome, and contin-
ued use is associated with a particularly adverse outcome.42
2.6.1.6. Recommendations for antiplatelet and an-
tithrombotic drugs. Table IV contains recommendations
for antiplatelet and antithrombotic drugs. See Appendix III
for supplemental information.
The writing group reviewed 5 RCTs and 1 meta-
analysis related to antiplatelet therapy and PAD as part of
this focused update.45–48,51 Although the 2002 Anti-
thrombotic Trialists’ Collaboration meta-analysis demon-
strated a significant reduction in cardiovascular events
among symptomatic PAD patients randomized to anti-
platelet therapy versus placebo, there was significant heter-
ogeneity of enrollment criteria and antiplatelet dosing reg-
imens among the trials.44 The results of 3 RCTs of aspirin
use (100 mg daily) versus placebo for cardiovascular risk
reduction among patients with PAD have been published
since the 2005 guideline.45–47 These trials yielded mixed
results, with the 2 larger trials with longer duration of
follow-up demonstrating no benefit of aspirin.46,47 How-
ever, both of these studies enrolled only asymptomatic
patients derived from population screening (not clinical
Table III. Recommendations for smoking cessation
2005 Recommendation 2011 Focused U
Class I
1. Patients who are
smokers should
tobacco use at e
Evidence: A)
2. Patients should
and developing
include pharmac
a smoking cessat
Evidence: A)
Individuals with lower extremity PAD
who smoke cigarettes or use other
forms of tobacco should be advised
by each of their clinicians to stop
smoking and should be offered
comprehensive smoking cessation
interventions, including behavior
modification therapy, nicotine
replacement therapy, or bupropion.
(Level of Evidence: B)
3. Individuals with
smoke cigarettes
tobacco should
clinicians to stop
behavioral and p
(Level of Evidenc
4. In the absence o
compelling clini
the following ph
should be offere
and nicotine rep
(Level of Evidenc
PAD, Peripheral artery disease.populations) based on very mild decrements in ABI and thus represented relatively low-risk cohorts. The POPA-
AD (Prevention of Progression of Asymptomatic Dia-
etic Arterial Disease) study enrolled individuals with an
BI0.99, whereas the Aspirin for Asymptomatic Athero-
clerosis trial used a cutpoint of ABI 0.95 but calculated
he ABI using the lower pedal pressure at the ankle. This
ethod is in contrast to standard clinical practice (and this
uideline) of using the higher pedal pressure at the ankle
or determining ABI.46,47 These factors limit the general-
zability of the results to patients with clinical PAD who are
ymptomatic and/or have lower ABI values and face a
reater risk of ischemic events. The CLIPS (Critical Leg
schemia Prevention Study) trial, which was the smallest of
he 3 antiplatelet therapy trials reviewed, enrolled patients
ith more advanced PAD, defined by both symptoms
nd/or ABI values (ABI 0.85), and demonstrated a
ignificant reduction in cardiovascular ischemic events
mong subjects randomized to aspirin.45 Of note, this trial
as stopped early because of poor recruitment, with only
66 of a planned 2000 patients enrolled. The 2009 meta-
nalysis of aspirin therapy for patients with PAD demon-
trated a 34% risk reduction for nonfatal stroke among
articipants taking aspirin but no statistically significant
eduction in overall cardiovascular events.51 This study
ncluded the CLIPS and POPADAD trials but not the
spirin for Asymptomatic Atherosclerosis trial.
The recommended dose range of aspirin has been modi-
ed to 75mg to 325mg per day to reflect the doses studied in
he aspirin clinical trials and in use in clinical practice. The
005 recommendation of clopidogrel as an alternative to
spirin therapy is unchanged. No new clinical trials have
irectly compared aspirin monotherapy therapy with clopi-
ogrel since the CAPRIE (Clopidogrel versus Aspirin in Pa-
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findings of the CHARISMA (Clopidogrel for High Athero-
thrombotic Risk and Ischemic Stabilization, Management,
and Avoidance) trial, it may be reasonable to consider combi-
nation antiplatelet therapy with aspirin plus clopidogrel for
certain high-risk patients with PAD who are not consid-
ered at increased risk of bleeding.48,49,52 Selection of an
antiplatelet regimen for the PAD patient should be
individualized on the basis of tolerance and other clinical
characteristics (ie, bleeding risk) along with cost and
Table IV. Recommendations for antiplatelet and antithro
2005 Recommendations 2011 Focused
Class I
Antiplatelet therapy is indicated to reduce
the risk of MI, stroke, or vascular death
in individuals with atherosclerotic
lower extremity PAD.
(Level of Evidence: A)
1. Antiplatelet thera
risk of MI, stroke
individuals with s
lower extremity P
intermittent clau
ischemia, prior lo
(endovascular or
for lower extremi
(Level of Evidence
Aspirin, in daily doses of 75 to 325 mg, is
recommended as safe and effective
antiplatelet therapy to reduce the risk
of MI, stroke, or vascular death in
individuals with atherosclerotic lower
extremity PAD. (Level of Evidence: A)
2. Aspirin, typically
is recommended
therapy to reduce
vascular death in
atherosclerotic lo
those with interm
limb ischemia, pr
revascularization
prior amputation
ischemia.44,45 (L
Clopidogrel (75 mg per day) is
recommended as an effective alternative
antiplatelet therapy to aspirin to reduce
the risk of MI, stroke, or vascular death
in individuals with atherosclerotic
lower extremity PAD.
(Level of Evidence: B)
3. Clopidogrel (75
a safe and effectiv
to aspirin to redu
stroke, or vascula
symptomatic athe
PAD, including t
claudication or cr
extremity revascu
surgical), or prior
ischemia.43 (Leve
Class IIa
1. Antiplatelet thera
risk of MI, stroke
asymptomatic ind
or equal to 0.90.
Class IIb
1. The usefulness of
the risk of MI, st
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well established.4
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events in patients
atherosclerotic lo
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limb ischemia, pr
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prior amputation
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who are at high p
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Class III: No benefit
Oral anticoagulation therapy with
warfarin is not indicated to reduce the
risk of adverse cardiovascular ischemic
events in individuals with
atherosclerotic lower extremity PAD.
(Level of Evidence: C)
1. In the absence of
warfarin, its addit
reduce the risk of
events in individu
extremity PAD is
harmful due to in
bleeding.50 (Leve
ABI, Ankle-brachial index; MI, myocardial infarction; and PAD, peripheralguidance from regulatory agencies. aThe WAVE (Warfarin Antiplatelet Vascular Evalua-
ion) trial provided further evidence against the use of oral
nticoagulation therapy in addition to antiplatelet therapy
or prevention of cardiovascular events among patients with
AD, and the level of evidence is upgraded to B for this
lass III recommendation.50
The writing group emphasizes that selection of the opti-
al antiplatelet therapy and determination of optimum dos-
ge in well-defined populations of patients with PAD are
ritical unanswered scientific questions. There is a need for
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November 2011e40 Rooke et alies to investigate the efficacy and risk of antiplatelet medica-
tions across the spectrum of PAD defined according to symp-
tom class (symptomatic versus asymptomatic) and objective
measures of atherosclerosis severity (ie, ABI value).
To date, no clinical trials have examined the efficacy of
new antithrombotic medications such as prasugrel, ticagre-
lor, or vorapaxar to reduce ischemic events in patients with
lower extremity PAD.
2.6.3. Recommendations for critical limb isch-
emia: Endovascular and open surgical treatment for
limb salvage. Table V contains recommendations for en-
dovascular and open surgical treatment for limb salvage in
patients with critical limb ischemia. See Appendix III for
supplemental information.
The writing group has reviewed the results of the
multicenter BASIL (Bypass Versus Angioplasty in Severe
Ischaemia of the Leg) trial funded by the United Kingdom
National Institute of Health Research andHealth Technol-
ogy Assessment Programme.54During a 5-year period, 452
patients with severe limb ischemia (characterized by rest/
night pain and tissue loss, such as skin ulceration and
gangrene, and thus including patients defined by this PAD
guideline syndrome term critical limb ischemia) were ran-
domly assigned to an initial treatment strategy of either
open surgery or balloon angioplasty. Major clinical out-
comes evaluated in this trial were amputation-free survival
and overall survival. The initial results published in 2005
indicated that in patients with severe limb ischemia due
to infrainguinal disease, the short-term clinical outcomes
Table V. Recommendations for critical limb ischemia: En
2005 Recommendations 2011 Focus
Class I
For individuals with combined inflow and
outflow disease with critical limb
ischemia, inflow lesions should be
addressed first. (Level of Evidence: C)
For individuals with combined inflow and
outflow disease in whom symptoms of
critical limb ischemia or infection
persist after inflow revascularization, an
outflow revascularization procedure
should be performed.53
(Level of Evidence: B)
If it is unclear whether hemodynamically
significant inflow disease exists, intra-
arterial pressure measurements across
suprainguinal lesions should be
measured before and after the
administration of a vasodilator.
(Level of Evidence: C)
Class IIa
1. For patients wi
extremity ische
expectancy of 2
whom an autog
available, ballo
perform when
improve distal
2. For patients wi
an estimated lif
bypass surgery,
autogenous vei
to perform as t
distal blood flobetween bypass surgery–first and balloon angioplasty– yrst were similar.54,55 These initial results showed that
ypass surgery–first was one third more expensive and
as associated with higher morbidity than balloon
ngioplasty–first.
The trial also initially suggested that after 2 years, patients
reated with balloon angioplasty–first had increased overall
urvival rates and fewer amputations. However, this early
nding was based on a post hoc analysis of a relatively small
umber of outcome events. Thus, more prolonged follow-up
as necessary to confirm or refute this finding. The results of
2.5-year follow-up have been published54 and confirm that
here was no significant difference in amputation-free survival
nd overall survival between the 2 treatment strategies. How-
ver, a bypass surgery–first approach was associated with a
ignificant increase in overall survival of 7.3 months (95% CI:
.2 to 13.4 months; P0.02) and a trend toward improved
mputation-free survival of 5.9 months (95% CI: 0.2 to 12.0
onths;P0.06) for those patients who survived for at least 2
ears after randomization. In summary, for all patients in the
rial, there was no significant difference between the 2 treat-
ent strategies in amputation-free survival or overall survival.
owever, these data suggest that it is reasonable for a bypass
urgery–first approach to be considered for these carefully
elected patients to prolong amputation-free survival and
verall survival. This study has also confirmed that the out-
omes following prosthetic bypass were extremely poor. Bal-
oon angioplasty, when possible, may be preferable to pros-
hetic bypass even in patients with a life expectancy of 2
scular and open surgical treatment for limb salvage
date Recommendations Comments
2005 recommendation remains
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update.
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update.
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update.
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ITS BRANCH VESSELS, AND THE LOWER
EXTREMITIES
5.2.8.1 Recommendations for management over-
view. Table VI contains recommendations for manage-
ment of abdominal aortic aneurysm (AAA). See Appendix
III for supplemental information.
Although the methods of treatment for infrarenal ab-
dominal aortic and iliac artery aneurysms have changed little
over the past 5 years, a greater understanding of the appropri-
ate application of these technologies and techniques has been
gained.Overall, open and endovascular repair techniques have
demonstrated clinical equivalence over time, with similar rates
of overall and aneurysm-related mortality and morbidity.
For patients with an infrarenal AAA who are likely to
live 2 years and who are good risk surgical candidates,
open or endovascular intervention is indicated. There is no
long-term advantage to either technique of aneurysm re-
pair. This was clearly demonstrated in 2 large multicenter,
Table VI. Recommendations for management of abdomin
2005 Recommendations 2011 Focused Upd
Class I
Open repair of infrarenal AAA and/or
common iliac aneurysms is
indicated in patients who are good
or average surgical candidates.
(Level of Evidence: B)
1. Open or endovas
infrarenal AAAs
aneurysms is ind
are good surgica
(Level of Evidenc
Periodic long-term surveillance
imaging should be performed to
monitor for an endoleak, to
document shrinkage or stability of
the excluded aneurysm sac, and to
determine the need for further
intervention in patients who have
undergone endovascular repair of
infrarenal aortic and/or iliac
aneurysms. (Level of Evidence: B)
2. Periodic long-ter
should be perfor
endoleak, confirm
document shrink
excluded aneurys
the need for furt
patients who hav
endovascular rep
and/or iliac aneu
(Level of Evidenc
Class IIa
Endovascular repair of infrarenal
aortic and/or common iliac
aneurysms is reasonable in patients
at high risk of complications from
open operations because of
cardiopulmonary or other
associated diseases.
(Level of Evidence: B)
1. Open aneurysm
perform in patien
surgical candidat
comply with the
surveillance requ
repair. (Level of E
Class IIb
Endovascular repair of infrarenal
aortic and/or common iliac
aneurysms may be considered in
patients at low or average surgical
risk. (Level of Evidence: B)
1. Endovascular rep
aneurysms in pat
surgical or anesth
by the presence o
cardiac, pulmona
is of uncertain ef
(Level of Evidenc
AAA, indicates abdominal aortic aneurysm.
*Indicates merging of deleted 2005 Class IIb recommendation with the mo
#1 recommendation.randomized, prospective studies. The EVAR (United lingdom Endovascular Aneurysm Repair) trial evaluated
he outcomes of patients 60 years of age who were
ppropriate candidates for either endovascular or open
epair of infrarenal AAAs that were at least 5.5 cm in
iameter based on computed tomographic imaging.56
ver 5 years, 1252 patients were enrolled and randomly
ssigned to either stent graft or open aneurysm repair. The
rimary outcomes measures were all-cause mortality and
neurysm-related mortality, and data were analyzed on an
ntention-to-treat basis. Follow-up was a minimum of 5
ears or until death, with a median postprocedural fol-
ow-up of 6 years. The treatment groups, which were 90.7%
ale with a mean age of 74 years, were uniform with regard
o comorbidities. There was a significant difference in pro-
edural mortality between endovascular and open repair
1.8% endovascular repair versus 4.3% open repair,
0.02, adjusted odds ratio: 0.39; 95% CI: 0.18 to 0.87).
ver time, this initial benefit was not sustained. Over the
eriod of observation, all-cause mortality in the endovascu-
rtic aneurysm
ecommendations Comments
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Modified recommendation (endovascular
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group (P0.72; adjustedHR: 1.03; 95%CI: 0.86 to 1.23).
Aneurysm-related mortality was also similar, with 1.0 death
per 100 person-years in the stent graft group compared
with 1.2 deaths per 100 person-years in the open-surgery
group (P0.73; adjustedHR: 0.92; 95%CI: 0.57 to 1.49).
Reintervention was required in 5.1% of patients treated
with an endograft but in only 1.7% of those who underwent
open surgery (P0.001), underscoring the need for careful
evaluation of the stent graft over time.56
These findings were consistent with those reported in
another multicenter, randomized, prospective trial.58 The
DREAM (Dutch Randomized Endovascular Aneurysm Re-
pair) trial evaluated the long-term outcomes of patients with
infrarenal aortic aneurysms 5 cm who were randomized to
either endovascular or open surgical treatment. The primary
outcome measure was all-cause mortality. There were no
differences in demographic characteristics or comorbidities
between the 178 patients assigned to open surgery and the
173 patients assigned to endovascular intervention. Similar to
the EVAR trial, the majority of patients in the DREAM trial
were male (91.7%), with a mean age of 70 years. The mini-
mum follow-up was 5 years, and the median was 6.4 years.
Over this period of time themortality rate of the 2 groups was
not different. The overall survival rate was 69.9% in the open-
surgery group and 68.9% among those undergoing stent graft
repair (difference: 1.0%; 95% CI: 8.8 to 10.8; P0.97).
Although cardiovascular disease was the single most common
cause of death, it accounted for only 33% of the deaths in the
open-surgery group and 27.6% of the deaths in the endovas-
cular treatment group.Deaths fromnoncardiovascular causes,
such as cancer, were more common. During the follow-up
period, freedom from secondary intervention was more com-
mon in the open-repair group compared with the endovascu-
lar treatment group (difference 11.5%; 95% CI: 2.0 to 21.0;
P0.03).58
More recently, a third trial has buttressed the results of the
EVAR andDREAM trials. TheOVER (Open Surgery Versus
Endovascular Repair Veterans Affairs Cooperative Study) trial
randomized 881 veterans with AAA 5 cm or an associated
iliac artery aneurysm 3 cm or an AAA 4.5 cm with rapid
enlargement to surgical or endovascular repair.60 The primary
outcome was long-term, all-cause mortality. As with both the
DREAM and EVAR trials, there were no differences in base-
line demographic characteristics. The trial participants were
overwhelmingly male (99%), white (87%), and current or
former smokers (95%). Over a mean follow-up of 1.8 years,
there was no statistical difference in mortality, 7% versus 9.8%
for endovascular and surgical repair, respectively (P0.13).
Interestingly, there were no differences in the rates of second-
ary therapeutic procedures or aneurysm-related hospitaliza-
tions between the groups, because increases in surgical com-
plications offset the number of secondary endovascular
repairs.
As with the EVAR trial, the DREAM and OVER trials
confirmed that the early benefits of endovascular aneurysm
repair, including a lower procedural mortality, are not sus-
tained. Therefore, the method of aneurysm repair that is eeemed to be most appropriate for each individual patient
hould be chosen.56,58,60 Endovascular treatment should not
e used in patients who do not meet the established anatom-
cal criteria orwho cannot complywith the required follow-up
maging requirements. Patients require either computed to-
ography or magnetic resonance imaging of the engrafted
egment of the aortoiliac segment at 1 month, 6 months, and
hen yearly to confirm that the graft has not moved and there
re no endoleaks that have resulted in repressurization and/or
rowth of the aneurysm sac. If patients cannot be offered the
ndicated long-term follow-up evaluation and treatment be-
ause of the lack of access to required imaging modalities or
nability to appropriately treat problematic endoleaks when
dentified, then endovascular repair should not be considered
he optimal treatment method. Open surgical repair is indi-
ated for those patients who do not meet the established
riteria for endovascular treatment.
A patient whose general physical condition is deemed
nsuitable for open aneurysm repair may not benefit from
ndovascular repair. This was suggested in a secondary
rotocol of the EVAR trial.56 The EVAR 2 trial random-
zed 404 patients with infrarenal aortic aneurysms of at least
.5 cm with comorbidities that prevented open repair to
eceive either endovascular treatment or no intervention.61
ne hundred ninety-seven patients were randomized to
he endovascular treatment group and 179 actually under-
ent stent graft placement. Of 207 patients randomly
ssigned to the no-treatment group, 70 had aneurysm
epair. The primary outcome was death from any cause.
he patients were followed up for a minimum of 5 years or
ntil death. The median follow-up period was 3.1 years.
hirty-day operative mortality was 7.3%. Although a signif-
cant difference in aneurysm-related mortality between the
groups was identified (3.6 deaths per 100 person-years
or endovascular therapy versus 7.3 deaths per 100 person-
ears without treatment, adjusted HR: 0.53; 95% CI: 0.32
o 0.89; P0.02), this was not associated with longer
urvival. During follow-up there was no significant differ-
nce in overall mortality between the 2 groups (21.0 deaths
er 100 person-years in the endovascular group versus 22.1
eaths per 100 person-years in the no-treatment group;
R for endovascular repair: 0.99; CI: 0.78 to 1.27;
0.97). Although there was no observed benefit to the
ndovascular treatment of infrarenal AAAs in patients
hose physical health was considered too poor to with-
tand open aneurysm repair in this trial, optimal manage-
ent of this challenging patient population has not been
efinitively established. Additional studies are required to
etter define the role of endovascular aneurysm repair in
atients with significantly impaired physical health who are
onsidered to be at high surgical or anesthetic risk.61
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medical therapy for
RAS: the ASTRAL
Investigators5
To review the clinical
benefit of
percutaneous
revascularization of
the renal arteries to
improve patency in
atherosclerotic
renovascular
disease
Randomized,
unblinded trial
806 Patients who had substantial
anatomical atherosclerotic
stenosis in 1 renal artery
that was considered
potentially suitable for
endovascular
revascularization and whose
physician was uncertain that
the patient would definitely
receive a worthwhile clinical
benefit from
revascularization, taking
into account the available
evidence
Patients who required
surgical
revascularization or
were considered to
have a high likelihood
of requiring
revascularization
within 6 mo, if they
had nonatheromatous
CV disease, or if they
had undergone
previous
revascularization for
RAS
Renal function, measured
by the reciprocal of the
serum creatinine level
Blood pressure, time
to renal and major
CV events, and
mortality
ABI combined with FRS
to predict CV events
and mortality: a meta-
analysis ABI
collaboration24
To determine if ABI
provides
information on risk
of CV events and
mortality
independent of
FRS and can
improve risk
prediction
Meta-analysis 24,955 men
and 23,339
women with
480,325 person-
years of follow-
up. Studies
included 16
population
cohort
studies.
Studies whose participants
were derived from a general
population, measured ABI
at baseline, and individual
followed up to detect total
and CV mortality
N/A
Outcomes following
endovascular vs open
repair of AAA: a
randomized trial60
To compare
postoperative
outcomes up to
2 y after
endovascular or
open repair of
AAA (interim
report of a 9-y
trial)
Randomized,
multicenter
clinical trial;
elective
endovascular
(n444) or open
(n437) repair of
AAA
881 Veterans (49 y old) from 42
VA Medical Centers with
eligible AAA who were
candidates for both elective
endovascular repair and
open repair of AAA
N/A Long-term (5 to 9 y) all-
cause mortality
2° outcomes
included:
1) procedure failure,
2) short-term major
morbidity,
3) in-hospital and
ICUs associated
with initial repair,
4) other procedure-
related morbidities
such as incisional
hernia or new or
worsened
claudication,
5) HRQOL, and
6) erectile dysfunction.
2° outcomes cover
short-term
perioperative period
Aspirin for prevention of
CV events in patients
with PAD: a meta-
analysis of randomized
trials51
To investigate the
effect of ASA on
CV event rates in
patients with PAD
Meta-analysis (18
trials involving
5269 persons
were identified)
N5269; 2823
patients taking
ASA (alone or
with
dipyridamole)
and 2446 in
control group
Inclusion criteria: 1)
prospective, RCTs either
open-label or blinded; 2)
assignment of PAD
participants to ASA
treatment or placebo or
control group; and 3)
available data on all-cause
mortality, CV death, MI,
stroke, and major bleeding
N/A CV events (nonfatal MI,
nonfatal stroke, and CV
death)
All-cause mortality,
major bleeding,
and individual
components of the
1° outcome
measure
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During a 5-y period, rate of progression of
renal impairment (as shown by the slope
of the reciprocal of the serum creatinine
level) was 0.07103 L/micromole/y
in the revascularization group, compared
with 0.13103 L/micromole/y in
the medical therapy group, a difference
favoring revascularization of 0.06103
L/micromole/y (95% CI: 0.002 to
0.13; P0.06). Over the same time,
mean serum creatinine level was 1.6
mmol/L (95% CI: 8.4 to 5.2 [0.02
mg/dL; 95% CI: 0.10 to 0.06]) lower
in the revascularization group than in the
medical therapy group. There was no
significance between-groups difference in
systolic blood pressure; decrease in
diastolic blood pressure was smaller in the
revascularization group than in the
medical-therapy group.
Revascularization group: P0.88;
95% CI: 1.40; 0.67 to 1.40
Major CV events: P0.61; 95% CI:
0.75 to 1.1
Death: P0.46; 95% CI: 0.69 to
1.18
The 2 study groups had similar
rates of renal events.
Revascularization group: HR:
0.97; 95% CI: 0.67 to 1.40;
P0.88
Major CV events: HR: 0.94; 95%
CI: 0.75 to 1.19; P0.61
Death: HR: 0.90; 95% CI: 0.69 to
1.18; P0.46
There are substantial risks but no
evidence of a worthwhile clinical
benefit from revascularization in
patients with atherosclerotic
renovascular disease.
Power80%, ITT analysis
Risk of death by ABI had a reverse J-shaped
distribution with a normal (low-risk) ABI
of 1.11 to 1.40. 10-y CV mortality in men
with low ABI (0.90) was 18.7% (95% CI:
13.3% to 24.1%) and with normal ABI
(1.11 to 1.40) was 4.4% (95% CI: 3.2% to
5.7%). Corresponding mortalities in
women were 12.6% (95% CI: 6.2% to
19.0%) and 4.1% (95% CI: 2.2% to 6.1%).
Low ABI (0.90) was associated with
approximately twice the 10-y total
mortality, CV mortality, and major
coronary event rate compared with the
overall rate in each FRS category. Inclusion
of ABI in CV risk stratification using the
FRS would result in reclassification of risk
category and modification of treatment
recommendations in19% of men and
36% of women.
10-y CV mortality:
Men: HR: 4.2; 95% CI: 3.3 to 5.4
Women: HR: 3.5; 95% CI: 2.4 to
5.1
Measurement of ABI may improve
accuracy of CV risk prediction
beyond FRS.
Relevant studies were identified. A
search of MEDLINE (1950 to
February 2008) and EMBASE
(1980 to February 2008) was
conducted using common text
words for the term ABI
combined with text words and
medical subject headings to
capture prospective cohort
designs.
Perioperative mortality (30-d or inpatient)
was lower for endovascular repair (0.5%
vs 3.0%; P0.004); no significant
difference in mortality at 2 y (7.0% vs
9.8%; P0.13). Patients in endovascular
repair group had reduced median
procedure time (2.9 vs 3.7 h), blood loss
(200 vs 1000 mL), transfusion
requirement (0 vs 1.0 units), duration of
mechanical ventilation (3.6 vs 5.0 h),
hospital stay (3 vs 7 d), and ICU stay (1
vs 4 d), but required substantial exposure
to fluoroscopy and contrast. No
differences between the 2 groups in
major morbidity, procedure failure, 2°
therapeutic procedures, aneurysm-related
hospitalizations, HRQOL, or erectile
function.
Perioperative mortality: P0.004;
Mortality at 2 y: P0.13
HR: 0.7; 95% CI: 0.4 to 1.1 Short-term outcomes after elective
AAA repair, perioperative
mortality was low for both
procedures and lower for
endovascular than open repair.
Early advantage of endovascular
repair was not offset by increased
morbidity or mortality in the first
2 y after repair. Long-term
outcome data are needed.
Analysis by ITT. Trial is ongoing,
and report covers October 15,
2002 through October 15,
2008.
5000 patient meta-analysis with 88%
power to detect a 25% difference (from
10% to 7.5%) and 70% power to detect a
20% difference (from 10% to 8%) in RR
of CV death, MI, or stroke in the ASA
group vs placebo or control groups.
Patient characteristics, ASA dosages, and
length of follow-up differed across
studies, so RR for each study was
assumed to have a random offset from the
population mean RR (ie, a random-
effects model). The Cochran Q statistic
and I2 statistic were calculated by study
authors to assess degree of heterogeneity
among the trials.
Effect of any ASA on prevention of
composite CV endpoints,
P0.13.
Effect of any ASA on prevention of
nonfatal MI, nonfatal stroke, and
CV death P0.81;
Nonfatal stroke, P0.02;
CV death, P0.59
Effect of any ASA on prevention of
any death and major bleeding:
Any death, P0.85
Major bleeding, P0.98.
Effect of ASA monotherapy on
prevention of adverse outcomes
composite CV endpoints, P0.21
Effect of any ASA on prevention
of composite CV endpoints:
RR: 0.88; 95% CI: 0.76 to 1.04
Effect of any ASA on prevention
of nonfatal MI, nonfatal stroke,
and CV death:
Nonfatal MI: RR: 1.04; 95% CI:
0.78 to 1.39
Nonfatal stroke: RR: 0.66; 95%
CI: 0.47 to 0.94CV death: RR:
0.94; 95% CI: 0.74 to 1.19
ASA effect on prevention of any
death and major bleeding:
Any death RR: 0.98; 95% CI: 0.83
to 1.17
Major bleeding: RR: 0.99; 95%
CI: 0.66 to 1.50
Effect of ASA monotherapy on
prevention of adverse outcomes:
Composite CV endpoints: RR:
0.75; 95% CI: 0.48 to 1.18
Nonfatal stroke: RR: 0.64; 95%
In patients with PAD, treatment
with ASA alone or with
dipyridamole resulted in a
statistically nonsignificant decrease
in the 1° endpoint of CV events
and a significant reduction in
nonfatal stroke. Results for the 1°
endpoint may reflect limited
statistical power. Additional RCTs
are needed to establish a net
benefit and bleeding risks in PAD.
Outcome measures:
1° outcome was RR reduction of
ASA therapy on composite
endpoint of nonfatal MI,
nonfatal stroke, and CV death
in the population of patients
who received any ASA therapy
(with or without dipyridamole).
2° outcomes were all-cause
mortality with each component
of the 1° endpoint. The 1°
safety outcome evaluated
occurrence of major bleeding as
defined by each study. ITT
analysis used.CI: 0.42 to 0.99
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Aspirin for prevention of
CV events in a general
population screened for
a low ABI: an RCT47
To determine
effectiveness of
ASA in preventing
events in people
with a low ABI
identified on
screening of the
general population
ITT, double-blind
RCT
28,980 men and
women 50 to
75 y old
N/A N/A Composite of initial fatal
or nonfatal coronary
event or stroke or
revascularization
All initial vascular
events, defined as a
composite of a 1°
endpoint event or
angina,
intermittent
claudication, or
TIA; and all-cause
mortality
Prevention of progression
of arterial disease and
diabetes (POPADAD)
trial: factorial
randomized placebo-
controlled trial of
aspirin and antioxidants
in patients with diabetes
and asymptomatic
PAD46
To determine
whether ASA and
antioxidant
therapy, combined
or alone, are more
effective than
placebo in
reducing
development of
CV events in
patients with
diabetes mellitus
and asymptomatic
PAD
Multicenter,
randomized,
double-blind,
22 factorial,
placebo-
controlled trial
1276 Adults of either sex, 40 y
old, with type 1 or type 2
diabetes who were
determined to have
asymptomatic PAD as
detected by lower-than-
normal ABI (0.99). The
trial used a higher cut-off
point (0.99 vs 0.9) because
it is recognized that
calcification in the vessels of
people with diabetes can
produce a normal or high
ABI, even in the presence of
arterial disease.
People with evidence
of symptomatic
CV disease; those
who use ASA or
antioxidant therapy
on a regular basis;
those with peptic
ulceration, severe
dyspepsia, a bleeding
disorder, or
intolerance to ASA;
those with suspected
serious physical illness
(such as cancer),
which might have
been expected to
curtail life expectancy;
those with psychiatric
illness (reported by
their general
practitioner); those
with congenital heart
disease; and those
unable to give
informed consent
2 hierarchical composite
1° endpoints of death
from CAD or stroke,
nonfatal MI or stroke,
or amputation above the
ankle for CLI; and death
from CAD or stroke
N/A
Endovascular vs open
repair of AAA: the
United Kingdom
EVAR Trial
Investigators56
To investigate the
long-term
outcome of
endovascular repair
of AAA compared
with open repair
Randomized trial 1252 N/A (published in previous
reports61)
N/A (published in
previous reports61)
Death from any cause.
Also assessed:
aneurysm-related
death, graft-related
complications, and
graft-related
reinterventions
N/A
Endovascular repair of
aortic aneurysm in
patients physically
ineligible for open
repair: the United
Kingdom EVAR Trial
Investigators59
To investigate
whether
endovascular repair
reduces the rate of
death among
patients who were
considered
physically ineligible
for open surgical
repair
Randomized trial 404 N/A (see original study61) N/A (see original
study61)
Death from any cause.
Also assessed:
aneurysm-related
death, graft-related
complications, and
graft-related
reinterventions
N/A
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1° endpoint event: 13.5 per 1000 person-
years; 95% CI: 12.2 to 15.0. No
statistically significant difference was
found between groups (13.7 events per
1000 person-years in the ASA group vs
13.3 in the placebo group; HR: 1.03;
95% CI: 0.84 to 1.27).
2° endpoint (vascular event): 22.8 per
1000 person-years; 95% CI: 21.0 to
24.8, and no statistically significant
difference was found between groups
(22.8 events per 1000 person-years in
the ASA group vs 22.9 in the placebo
group; HR: 1.00; 95% CI: 0.85 to
1.17).
No significant difference in all-cause
mortality between groups, 176 vs 186
deaths, respectively; HR: 0.95; 95% CI:
0.77 to 1.16.
An initial event of major hemorrhage
requiring admission to hospital
occurred in 34 participants (2.5 per
1000 person-years) in the ASA group
and 20 (1.5 per 1000 person-years) in
the placebo group (HR: 1.71; 95% CI:
0.99 to 2.97).
1° endpoint: No statistically
significant difference was found
between groups. HR: 1.03; 95%
CI: 0.84 to 1.27
2° endpoint (vascular event): No
statistically significant difference
between groups, HR: 1.00; 95%
CI: 0.85 to 1.17All-cause
mortality: HR: 0.95; 95% CI:
0.77 to 1.16An initial event of
major hemorrhage requiring
admission: HR: 1.71; 95% CI:
0.99 to 2.97
Among participants without clinical
CV disease, identified with a low
ABI based on screening a general
population, administration of ASA
compared with placebo did not
result in a significant reduction in
vascular events.
Interventions: Once-daily 100 mg
ASA (enteric coated) or
placebo. Statistics: The trial was
powered to detect a 25%
proportional risk reduction in
major vascular events. Predicted
risk reduction evidence from 1)
event rates in asymptomatic
participants with a low ABI
were similar to those with
symptomatic PAD, suggesting
that the risk reduction could be
comparable with patients who
have clinical disease (25% to
15%), and 2) in stable angina,
unlike ACS with thrombosis
complicating atherosclerotic
plaque, risk reduction could
reach 33%. Study termination:
Subsequently, DSMB stopped
the trial 14 mo early due to the
improbability of finding a
difference in the 1° endpoint by
the end date and an increase in
major bleeding (P0.05) in the
ASA group. Even though the
trial was stopped early, the
required number of events was
achieved.
Overall, 116 of 638 1° events occurred in
the ASA groups compared with 117 of
638 in the no-ASA groups (18.2% vs
18.3%); 43 deaths from CAD or stroke
in the ASA groups compared with 35 in
the no-ASA groups (6.7% vs 5.5%).
Among the antioxidant groups, 117 of
640 (18.3%) 1° events occurred
compared with 116 of 636 (18.2%) in
the no-antioxidant groups. There were
42 deaths (6.6%) from CAD or stroke
in the antioxidant groups compared
with 36 deaths (5.7%) in the no-
antioxidant groups.
Comparison of ASA and no-ASA
groups—Composite endpoint:
P0.86
Death from CAD or stroke: P0.36
Comparison of antioxidant and no-
antioxidant groups—Composite
endpoint: P0.85
Death from CAD or stroke: P0.40
ASA groups 1° events: HR: 0.98;
95% CI: 0.76 to 1.26
ASA groups deaths from CAD or
stroke HR: 1.23 (0.79 to 1.93)
Antioxidant groups 1° events: HR:
1.03; 95% CI: 0.79 to 1.33
Antioxidant groups deaths from
CAD or stroke: HR: 1.21; 95%
CI: 0.78 to 1.89
This trial does not provide evidence
to support the use of ASA or
antioxidants in primary prevention
of CV events and mortality in the
population with diabetes studied.
Power: 1276 patients were
recruited, and final power
calculations, undertaken in
2003, projected that if follow-
up continued until June 2006,
then 256 events would be
expected to occur during the
trial. This would give 73%
power to detect a 25% relative
reduction in event rate and 89%
power to detect a 30%
reduction in event rate if only 1
treatment was effective.
Interventions were daily ASA
100 mg or placebo tablet, plus
antioxidant or placebo capsule.
The antioxidant capsule
contained -tocopherol 200
mg, ascorbic acid 100 mg,
pyridoxine hydrochloride 25
mg, zinc sulphate 10 mg,
nicotinamide 10 mg, lecithin
9.4 mg, and sodium selenite 0.8
mg.
30-d operative mortality was 1.8% in the
endovascular repair group and 4.3% in
the open-repair group.
30-d operative mortality (for
endovascular repair compared
with open repair): P0.02
Aneurysm-related mortality:
P0.73
Rate of death from any cause:
P0.72
30-d operative mortality (for
endovascular repair compared
with open repair): adjusted OR:
0.39; 95% CI: 0.18 to 0.87
Aneurysm-related mortality:
adjusted HR: 0.92; 95% CI:
0.57 to 1.49
Rate of death from any cause:
adjusted HR: 1.03; 95% CI:
0.86 to 1.23
Endovascular repair of AAA was
associated with a significantly
lower operative mortality than
open surgical repair. However, no
differences were seen in total
mortality or aneurysm-related
mortality in the long term.
Endovascular repair was associated
with increased rates of graft-
related complications and
reinterventions and was more
costly.
Rates of graft-related
complications and
reinterventions were higher
with endovascular repair, and
new complications occurred up
to 8 y after randomization,
contributing to higher overall
costs. Per-protocol analysis
yielded results very similar to
those of ITT analysis.
30-d operative mortality was 7.3% in the
endovascular repair group. The overall
rate of aneurysm rupture in the no-
intervention group was 12.4 (95% CI:
9.6 to 16.2) per 100 person-years. A
total of 48% of patients who survived
endovascular repair had graft-related
complications, and 27% required
reintervention within the first 6 y.
Aneurysm-related mortality:
P0.02
Total mortality: P0.97
Aneurysm-related mortality was
lower in the endovascular repair
group. Adjusted HR: 0.53; 95%
CI: 0.32 to 0.89.
Total mortality: adjusted HR:
0.99; 95% CI: 0.78 to 1.27
This RCT involved patients who
were physically ineligible for open
repair; endovascular repair of AAA
was associated with a significantly
lower rate of aneurysm-related
mortality than no repair.
However, endovascular repair was
not associated with reduction in
the rate of death from any cause.
Rates of graft-related
complications and reinterventions
were higher with endovascular
During 8 y of follow-up,
endovascular repair was
considerably more expensive
than no repair (cost difference,
£9826 [US $14,867]; 95% CI:
£7638 to £12,013 [$11,556 to
$18,176]).repair, and it was more costly.
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BASIL54 An ITT analysis of
AFS and OS in
patients
randomized to a
BSX-first or a
BAP-first
revascularization
strategy
Randomized trial 452 BASIL trial methods have
been published in detail
elsewhere.55
BASIL trial methods
have been published
in detail elsewhere.55
1° aim: determine whether
a BSX-first or a BAP-first
revascularization strategy
was associated with
better clinical outcome
for patients. Defined
better as improved AFS;
used this as 1° endpoint
for power calculation and
prespecified statistical
plan design.
2° outcomes included
postprocedural
morbidity,
reinterventions,
HRQOL, and use
of hospital
resources.
Statins are independently
associated with reduced
mortality in patients
undergoing IBG
surgery for CLI
(PREVENT III)62
To determine
efficacy of
edifoligide for
prevention of graft
failure
Multicenter,
randomized,
prospective trial
1404 patients
with CLI
Patients 18 y old who
underwent IBG with
autogenous vein for CLI,
defined as gangrene,
nonhealing ischemic ulcer,
or ischemic rest pain. See
primary trial report for
further information.63
Claudication as an
indication for IBG
surgery or use of a
nonautogenous
conduit. See primary
trial report for further
information.63
Major adverse CV
events 30 d, vein
graft patency,
and 1-y survival
assessed by
Kaplan-Meier
method
N/A
Mortality and vascular
morbidity in older
adults with
asymptomatic vs
symptomatic PAD
(getABI)11
To assess risk of
mortality and
vascular morbidity
in elderly persons
with asymptomatic
vs symptomatic
PAD in the
primary care
setting
Prospective cohort
study
6880 representative
unselected
patients 65 y of
age: 5392
patients had no
PAD, 836 had
asymptomatic
PAD (ABI: 0.9
without
symptoms), and
593 had
symptomatic
PAD (lower
extremity
peripheral
revascularization,
amputation as a
result of PAD, or
intermittent
claudication
symptoms
regardless of
ABI)
Age 65 y, legally
competent, and able to
cooperate appropriately
and provide written
informed consent64
Life expectancy of 6 mo
as judged by the
general practitioner64
1° outcomes and
identification of CV
events during follow-up:
severe vascular events
were defined as follows:
CV, including MI or
coronary
revascularization;
cerebrovascular,
including stroke or
carotid revascularization;
and lower extremity
peripheral vascular,
including peripheral
revascularization or
amputation because of
PAD during follow-up.
N/A
Effectiveness of
a smoking cessation
program for PAD
patients65
To test the
effectiveness of a
smoking cessation
program designed
for patients with
PAD
RCT 124 Diagnosis of lower extremity
PAD, defined as at least 1 of
the following: ABI0.90 in
at least 1 lower extremity; toe
brachial index0.60;
objective evidence of arterial
occlusive disease in 1 lower
extremity by duplex
ultrasound, MRA, or CTA;
prior leg arterial
revascularization or
amputation due to PAD, and
current smoking (defined as
smoking at least 1 cigarette/
d, at least 6 d/wk).
Additional inclusion criteria:
desire to quit smoking in the
next 30 d, age18 y, ability
to speak and write English,
no participation in a smoking
cessation program in the past
30 d, and consumption of
N/A Tobacco use 7-d point
prevalence of smoking
(ie, “Have you smoked a
cigarette, even a puff, in
the past 7 d?”), at the 3-
and 6-mo follow-ups
N/A21 alcoholic drinks per wk.
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For those patients who survived for 2 y
after randomization: initial
randomization to a BSX-first
revascularization strategy was associated
with an increase in subsequent
restricted mean overall survival of 7.3
mo (95% CI: 1.2 to 13.4 mo) and an
increase in restricted mean AFS of 5.9
mo (95% CI: 0.2 to 12.0 mo) during
the subsequent mean follow-up of 3.1 y
(range: 1 to 5.7 y).
For those patients surviving 2 y
from randomization: BSX-first
revascularization was associated
with subsequent AFS of P0.108
and subsequent OS of P0.009.
For those patients who survived for
2 y after randomization: initial
randomization to a BSX-first
revascularization strategy was
associated with an increase in
subsequent restricted mean
overall survival, P0.02, and an
increase in restricted mean AFS,
P0.06.
For those patients surviving 2 y
from randomization: BSX-first
revascularization was associated
with reduced HR for
subsequent AFS of 0.85 (95%
CI: 0.5 to 1.07) in an adjusted,
time-dependent Cox
proportional hazards model and
subsequent OS of 0.61 (95%
CI: 0.50 to 0.75) in an
adjusted, time-dependent Cox
proportional hazards model.
Overall there was no significant
difference in AFS or OS between
the 2 strategies. However, for
those patients who survived for
2 y after randomization, a BSX-
first revascularization strategy was
associated with a significant
increase in subsequent OS and a
trend toward improved AFS.
The sample size calculations
proposed that 223 patients per
treatment would be needed for
90% power to detect a 15%
difference in 3-y AFS at the 5%
significance level. This
calculation was based on the
assumption that the 3-y survival
value might be 50% in 1 group
and 65% in the others.
Patient treatment breakdown: 636
patients (45%) were taking statins, 835
(59%) were taking beta blockers, and
1121 (80%) were taking antiplatelet
drugs. Perioperative major adverse CV
events (7.8%) and early mortality (2.7%)
were not measurably affected by use of
any drug class. Use of beta blockers and
antiplatelet drugs had no appreciable
impact on survival. None of the drug
classes were associated with graft
patency measures at 1 y. Statin use was
associated with a significant survival
advantage at 1 y of 86% vs 81% by
analysis of both unweighted and
propensity score–weighted data.
Statin use associated with significant
survival advantage at 1 y: P0.03
Significant predictors of 1-y
mortality by Cox regression
modeling were:
Statin use P0.001
Age 75 y, P0.001
CAD, P0.001
CKD stage 4, P0.001
CKD stage 5, P0.001
Tissue loss, P0.003
Statin use associated with a
significant survival advantage at
1 y: HR: 0.71; 95% CI 0.52 to
0.98
Significant predictors of 1-y
mortality by Cox regression
modeling were:
Statin use HR: 0.67; 95% CI: 0.51
to 0.90 Age 75 y HR: 2.1;
95% CI: 1.60 to 2.82
CAD HR: 1.5; 95% CI: 1.15 to
2.01
CKD stage 4 HR: 2.0; 95% CI:
1.17 to 3.55
CKD stage 5 HR: 3.4; 95% CI:
2.39 to 4.73
Tissue loss HR: 1.9; 95% CI: 1.23
to 2.80
Statin use was associated with
improved survival in CLI patients
1 y after surgical revascularization.
Further studies are indicated to
determine optimal dosing in this
population and to definitively
address the question of
relationship to graft patency.
These data add to the growing
literature supporting statin use in
patients with advanced PAD.
Propensity scores used to evaluate
the influence of statins, beta
blockers, and antiplatelet agents
on outcomes while adjusting for
demographics, comorbidities,
medications, and surgical
variables that may influence
drug use.
Lower ABI categories were associated
with increased risk. PAD was a strong
factor for prediction of the composite
endpoint in an adjusted model.
Risk of symptomatic compared
with asymptomatic PAD
patients:
Composite of all-cause death or
severe vascular event HR: 1.48;
95% CI: 1.21 to 1.80
All-cause death alone HR: 0.13,
95% CI: 0.89 to 1.43
All-cause death/MI/stroke
(excluding lower extremity
peripheral vascular events and
any revascularizations) HR:
1.18; 95% CI: 0.92 to 1.52
CV events alone HR: 1.20; 95%
CI: 0.89 to 1.60
Cerebrovascular events alone HR:
1.33; 95% CI: 0.80 to 2.20
Asymptomatic PAD diagnosed
through routine screening in
offices of PCPs has a high and/or
vascular event risk. Notably, risk
of mortality was similar in
symptomatic and asymptomatic
patients with PAD and was
significantly higher than in those
without PAD. In the primary care
setting, the diagnosis of PAD has
important prognostic value.
Incidence rates and 95% CIs were
calculated as events per 1000
person-years. The composite
endpoint of all-cause mortality
or severe vascular events
occurred in 27.2 (no PAD),
60.4 (asymptomatic PAD), and
104.7 (symptomatic PAD) cases
per 1000 patient-years.
In analysis by ABI category,
patients with an ABI of 1.1 to
1.5 had the lowest event rate
per 1000 patient-years (24.3
events), whereas event rates
increased substantially with
decreasing ABI. In patients with
an ABI of 0.5, lower extremity
peripheral revascularization, or
amputation resulting from
PAD, event rates were increased
6-fold (146.3), and the
corresponding adjusted risk was
increased 4.65-fold (95% CI:
3.57 to 6.05).
Participants randomized to the intensive
intervention group were significantly
more likely to be confirmed abstinent at
6-mo follow-up: 21.3% vs 6.8% in the
minimal intervention group: chi-
squared5.21.
Members of the intensive
intervention group were
significantly more likely to be
confirmed abstinent at 6-mo
follow-up: P0.023.
N/A Many long-term smokers with PAD
are willing to initiate a serious quit
attempt and to engage in an
intensive smoking cessation
program. Intensive intervention
for tobacco dependence is a more
effective smoking cessation
intervention than minimal care.
Studies should be conducted to
examine the long-term
effectiveness of intensive smoking
cessation programs in this
population in order to examine
the effect of this intervention on
clinical outcomes related to PAD.
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Prevention of serious
vascular events by
aspirin among patients
with PAD: randomized,
double-blind trial:
CLIPS Group45
To assess the
prophylactic
efficacy of ASA and
a high-dose
antioxidant vitamin
combination in
patients with PAD
in terms of
reduction of risk of
a first vascular
event (MI, stroke,
vascular death) and
CLI
RCT, double-blind
clinical trial with
22 factorial
design
366 outpatients
with stage I to
II PAD
documented by
angiography or
ultrasound, with
ABI 0.85 or
toe index 0.6
Study involved outpatients
with symptomatic
(claudicant) or
asymptomatic PAD
documented by
angiography or ultrasound,
who had 1 ABI 0.85 or 1
toe index 0.6. Patients
were referred either by the
GP or ER physician for a
diagnostic workup. Diabetic
persons could be included,
provided metabolic control
was stable (HbA1c). Only
patients who accepted
randomization (ie,
continuation after run-in
period) were included in the
study.
Exclusion criteria:
Fontaine stage III or
IV PVD; life
expectancy 24 mo;
vascular surgery or
angioplasty in the last
3 mo; pregnancy or
lactation;
contraindication to
ASA; major CV
events requiring
antiplatelet therapy;
participation in
another clinical trial;
uncooperative
patients; treatment
with drugs that
interfere with
hemostasis, such as
anticoagulants,
antiplatelet agents,
and prostanoids,
peripheral
vasodilators, ASA
and/or
supplementary
vitamins that could
not be discontinued
or had to be
introduced
Major vascular events:
CV death, MI, or
stroke and CLI
N/A
Patients with PAD in the
CHARISMA trial49
To determine
whether
clopidogrel plus
ASA provides
greater protection
against major CV
events than ASA
alone in patients
with PAD
Prospective,
multicenter,
randomized,
double-blind,
placebo-
controlled study
3096 patients with
symptomatic
(2838) or
asymptomatic
(258) PAD
To fulfill the symptomatic
PAD inclusion criterion,
patients had to have either
current intermittent
claudication together with
an ABI of 0.85 or a history
of intermittent claudication
together with a previous
related intervention
(amputation, surgical or
catheter-based peripheral
revascularization).
Asymptomatic patients with
an ABI of 0.90 were
identified among those with
multiple risk factors.
The details of the trial
design have been
published
previously66
1° efficacy endpoint: first
occurrence of MI, stroke
(of any cause), or death
from CV causes
(including hemorrhage).
1° safety endpoint: severe
bleeding according to the
GUSTO definition
Principal 2° efficacy
endpoints: first
occurrence of MI,
stroke, death from
CV causes,
hospitalization for
UA, TIA, or a
revascularization
procedure
(coronary, cerebral,
or peripheral)
CHARISMA48 To view dual
antiplatelet therapy
with clopidogrel
plus low-dose ASA
in a broad
population of
patients at high
risk for
atherothrombotic
events
Prospective,
multicenter,
randomized,
double-blind,
placebo-
controlled study
15 603 See study for the inclusion
criteria for those with
multiple risk factors and
those with established
vascular disease.
Patients were excluded
from the trial if they
were taking oral
antithrombotic
medications or NSAIDs
on a long-term basis
(although COX-2
inhibitors were
permitted). Patients
were also excluded if, in
the judgment of the
investigator, they had
established indications
for clopidogrel therapy
(such as recent ACS).
Patients who were
scheduled to undergo
revascularization were
not allowed to enroll
until the procedure had
been completed; such
patients were excluded
if they were considered
to require clopidogrel
1° efficacy endpoint:
composite of MI, stroke,
or death from CV causes.
1° safety endpoint: severe
bleeding, according to
the GUSTO definition
Principal 2° efficacy
endpoint: first
occurrence of MI,
stroke, death from
CV causes, or
hospitalization for
UA, TIA, or a
revascularization
procedure
(coronary, cerebral,
or peripheral)after revascularization.
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7 of 185 patients who were allocated to
ASA and 20 of 181 patients who were
allocated to placebo suffered a major
vascular event (risk reduction 64%). 5
and 8 patients, respectively, suffered
CLI (total 12 vs 28).
There was no evidence that antioxidant
vitamins were beneficial (16/185 vs
11/181 vascular events).
Neither treatment was associated with any
significant increase in adverse events.
Major vascular event: P0.022;
CLI: P0.014
N/A For the first time direct evidence
shows that low-dose ASA should
routinely be considered for
patients with PAD, including
those with concomitant type 2
diabetes.
The safety endpoint was incidence
of bleeding. Inclusion of this
trial in a meta-analysis of other
RCTs of antiplatelet therapy in
PAD makes the overall results
highly significant (P0.001)
and suggests that low-dose ASA
reduces the incidence of
vascular events by 26%.
Post hoc analysis of the 3096 patients
with symptomatic (2838) or
asymptomatic (258) PAD from the
CHARISMA trial. CV death, MI, or
stroke rates (1° endpoint) were higher
in PAD patients than in those without
PAD: 8.2% vs 6.8%. Severe, fatal, or
moderate bleeding rates did not differ
between groups, whereas minor
bleeding was increased with
clopidogrel: 34.4% vs 20.8%.
Among patients with PAD:
The 1° endpoint occurred in 7.6% in the
clopidogrel plus ASA group and 8.9% in
the placebo plus ASA group.
The rate of MI was lower in the dual
antiplatelet arm than the ASA-alone
arm: 2.3% vs 3.7%.
The rate of hospitalization for ischemic
events: 16.5% vs 20.1%.
Rates of minor bleeding: OR:
1.99; 95% CI: 1.69 to 2.34.
Among the patients with PAD:
1° endpoint: HR: 0.85; 95% CI:
0.66 to 1.08
Rate of MI: HR: 0.63; 95% CI:
0.42 to 0.96
Rate of hospitalization: HR: 0.81;
95% CI: 0.68 to 0.95
Rate of hospitalization for
ischemic events: HR: 0.81; 95%
CI: 0.68 to 0.95
Dual therapy provided some benefit
over ASA alone in PAD patients
for the rate of MI and the rate of
hospitalization for ischemic
events, at cost of an increase in
minor bleeding.
N/A
1° efficacy rate endpoint: 6.8% with
clopidogrel plus ASA and 7.3% with
placebo plus ASA. Principal 2° efficacy
rate endpoint, including
hospitalizations for ischemic events, was
16.7% and 17.9%. Principal 2° efficacy
endpoint, including the rate of severe
bleeding, 1.7% and 1.3%. 1° endpoint
rate among patients with multiple risk
factors was 6.6% with clopidogrel and
5.5% with placebo. The rate of death
from CV causes also was higher with
clopidogrel (3.9% vs 2.2%). In the
subgroup with clinically evident
atherothrombosis, the rate was 6.9%
with clopidogrel and 7.9% with
placebo.
1° endpoint rate among patients
with multiple risk factors: P0.20
1° endpoint rate in the subgroup
with clinically evident
atherothrombosis: P0.046
Rate of death from CV causes:
P0.01
1° efficacy endpoint rate: P0.22
Principal 2° efficacy rate endpoint,
including rate of severe bleeding:
P0.09
Principal 2° efficacy rate endpoint,
including hospitalizations for
ischemic events: P0.04
1° efficacy endpoint rate: RR 0.93;
95% CI: 0.83 to 1.05
1° endpoint rate in subgroup with
clinically evident
atherothrombosis: RR: 0.88;
95% CI: 0.77 to 0.998
1° endpoint rate among patients
with multiple risk factors: RR:
1.2; 95% CI: 0.91 to 1.59
Principal 2° efficacy endpoint,
including the rate of severe
bleeding: RR: 1.25, 95% CI:
0.97 to 1.61.
Principal 2° efficacy rate endpoint,
including hospitalizations for
ischemic events: RR: 0.92; 95%
CI: 0.86 to 0.995
There was a suggestion of benefit
with clopidogrel treatment in
patients with symptomatic
atherothrombosis and a
suggestion of harm in patients
with multiple risk factors. Overall,
clopidogrel plus ASA was not
significantly more effective than
ASA alone in reducing rate of MI,
stroke, or death from CV causes.
Other efficacy endpoints included
death from any cause and death
from CV causes, as well as MI,
ischemic stroke, any stroke, and
hospitalization for UA, TIA, or
revascularization considered
separately.
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Study Title Aim of Study Study Type Study Size
Patient Population/Inclusion and Exclusion Criteria Endpoints
Inclusion Exclusion Primary Secondary
Oral anticoagulant and
antiplatelet therapy and
PAD: the WAVE trial
Investigators50
To view the role of
oral anticoagulants
in prevention of
CV complications
in patients with
PAD
Randomized, open-
label, clinical trial
2161 patients Men and women who were
35 to 85 y old and had
PAD
Patients who had an
indication for oral
anticoagulant
treatment, were
actively bleeding or at
high risk for bleeding,
had had a stroke
within 6 mo before
enrollment, or
required dialysis
First coprimary outcome:
MI, stroke, or death
from CV causes. Second
coprimary outcome: MI,
stroke, severe ischemia of
the peripheral or
coronary arteries leading
to urgent intervention, or
death from CV causes
N/A
AAA, Abdominal Aortic and Iliac Aneurysms; ABI, ankle brachial index; ACS, acute coronary syndrome; AFS, amputation-free survival; ASA, aspirin;
ASTRAL, Angioplasty and Stent for Renal Artery Lesions trial; BAP, balloon angioplasty; BASIL, Bypass versus Angioplasty in Severe Ischaemia of the Leg
trial; BSX-first, bypass surgery; CAD, coronary artery disease; CHARISMA, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization,
Management, and Avoidance; CI, confidence interval; CKD, chronic kidney disease; CLI, critical limb ischemia; CLIPS, Critical Leg Ischemia Prevention
Study; COX-2, cyclooxygenase; CTA, computed tomographic angiography; CV, cardiovascular; DSMB, data safety monitoring board; Embase, Excerpta
Medica Database; ER, emergency room; EVAR, endovascular aneurysm repair; FRS, Framingham Risk Score; GP, general practitioner; GUSTO, Global
Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries; HbA1c, hemoglobin A1c; HR; hazard ratio; HRQOL,
health-related quality of life; IBG, infrainguinal bypass graft; ICU, intensive care unit; ITT, intention-to-treat; MEDLINE, Medical Literature Analysis and
Retrieval System Online; MI, myocardial infarction; N/A, not available; NSAIDs, nonsteroidal anti-inflammatory drugs; OR, odds radio; OS, overall survival;
MRA, magnetic resonance angiography; PAD, peripheral artery disease; PCP, primary care physician; POPADAD, prevention of progression of arterial disease
and diabetes; PREVENT III, The Project of Ex-Vivo Vein Graft Engineering via Transfection III; PVD, peripheral vascular disease; RAS, renal artery stenosis;
RCT, randomized controlled trial;RR, relative risk; SLI, severe leg ischemia;TIA, transient ischemic attack;UA, unstable angina;VA, Department of Veterans
Affairs; WAVE, Warfarin Antiplatelet Vascular Evaluation trial; 1°, primary; and 2°, secondary.
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Statistical Analysis (Results) P (95% CI) OR/HR/RR
Study Conclusion (as Reported in
Study Article) Other Information
MI, stroke, or death from CV causes
occurred in 132 of 1080 patients
receiving combination therapy (12.2%)
and in 144 of 1081 patients receiving
antiplatelet therapy alone (13.3%). MI,
stroke, severe ischemia, or death from
CV causes occurred in 172 patients
receiving combination therapy (15.9%)
compared with 188 patients receiving
antiplatelet therapy alone (17.4%). Life-
threatening bleeding occurred in 43
patients receiving combination therapy
(4.0%) compared with 13 patients
receiving antiplatelet therapy alone
MI, stroke, or death from CV
causes: P0.48
MI, stroke, severe ischemia, or
death from CV causes: P0.37
Life-threatening bleeding: P0.001
MI, stroke, or death from CV
causes: RR: 0.92; 95% CI: 0.73
to 1.16
MI, stroke, severe ischemia, or
death from CV causes: RR:
0.91; 95% CI: 0.74 to 1.12
Life-threatening bleeding: RR:
3.41; 95% CI: 1.84 to 6.35
The combination of an oral
anticoagulant and antiplatelet
therapy was no more effective than
antiplatelet therapy alone in
preventing major CV
complications and was associated
with an increase in life-threatening
bleeding.
Safety outcomes were life-
threatening, moderate, or
minor bleeding episodes.(1.2%).
